down arrow

Ikena Oncology, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US45175G1085
USD
6.78
0.57 (9.18%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

6.597.07

52 Week

0.9718.00
Valuation
Technical
Day's Volume

CASH

26.95 k

Shareholding (Mar 2025)

FII

3.51%

Held by 21 FIIs

DII

16.83%

Held by 23 DIIs

Promoter

61.19%

How big is Ikena Oncology, Inc.?

22-Jun-2025

As of Jun 18, Ikena Oncology, Inc. has a market capitalization of 65.63 million, with net sales of 0.00 million and a net profit of -41.70 million over the last four quarters. The company reported shareholder's funds of 125.93 million and total assets of 141.51 million as of Dec 24.

Market Cap: As of Jun 18, Ikena Oncology, Inc. has a market capitalization of 65.63 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Ikena Oncology, Inc. reported net sales of 0.00 million and a net profit of -41.70 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 125.93 million and total assets of 141.51 million.

Read More

What does Ikena Oncology, Inc. do?

22-Jun-2025

Ikena Oncology, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $9 million and a market cap of $65.63 million. Key metrics include a negative P/E ratio, no dividend yield, and a return on equity of -32.50%.

Overview: <BR>Ikena Oncology, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -9 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 65.63 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.93 <BR>Return on Equity: -32.50% <BR>Price to Book: 0.56<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Ikena Oncology, Inc. overvalued or undervalued?

25-Jun-2025

As of November 7, 2024, Ikena Oncology, Inc. is considered overvalued and has been downgraded to "does not qualify" due to negative financial metrics, including a -32.50% ROE and poor performance compared to peers and the S&P 500, with a current stock price of 1.34.

As of 7 November 2024, Ikena Oncology, Inc. has moved from a valuation grade of risky to does not qualify, indicating a significant downgrade in its investment appeal. The company's current valuation suggests it is overvalued, particularly given its negative financial metrics. Key ratios include a Price to Book Value of 0.58 and an EV to EBITDA of 0.87, both of which reflect a lack of profitability and operational efficiency. The company's ROE stands at -32.50%, further underscoring its financial struggles.<BR><BR>In comparison to peers, Ikena's valuation metrics are less favorable; for instance, CorMedix, Inc. is considered expensive with a P/E of 55.03, while Vigil Neuroscience, Inc. and Neoleukin Therapeutics, Inc. also do not qualify but have less negative valuations. The stock has underperformed against the S&P 500, with a year-to-date return of -18.29% compared to the S&P's 2.44%, reinforcing the notion that Ikena is not a compelling investment at its current price of 1.34.

Read More

Is Ikena Oncology, Inc. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, Ikena Oncology, Inc. shows a mildly bullish trend with strong MACD and KST indicators, despite bearish signals from the RSI and On-Balance Volume, and has significantly outperformed the S&P 500 year-to-date with a return of 409.15%.

As of 4 September 2025, the technical trend for Ikena Oncology, Inc. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are bullish, while the monthly MACD is also bullish, indicating some strength in the trend. However, the monthly RSI is bearish, suggesting potential weakness. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, and the daily moving averages are also mildly bullish. Dow Theory shows a mildly bullish stance on the monthly chart, but the weekly chart indicates no trend. The On-Balance Volume is mildly bearish on both weekly and monthly time frames.<BR><BR>In terms of performance, Ikena has significantly outperformed the S&P 500 year-to-date with a return of 409.15% compared to the S&P's 12.22%, and over the past year, it has returned 403.01% versus the S&P's 17.14%. Overall, the current technical stance is mildly bullish, driven by the bullish MACD and KST, despite some bearish signals from the RSI and OBV.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 152 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.79

stock-summary
Return on Equity

-24.02%

stock-summary
Price to Book

1.31

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-50.57%
0%
-50.57%
6 Months
402.22%
0%
402.22%
1 Year
298.82%
0%
298.82%
2 Years
352.0%
0%
352.0%
3 Years
187.29%
0%
187.29%
4 Years
-43.5%
0%
-43.5%
5 Years
0%
0%
0.0%

Ikena Oncology, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Ikena Oncology, Inc. technically bullish or bearish?

As of 4 September 2025, the technical trend for Ikena Oncology, Inc. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are bullish, while the monthly MACD is also bullish, indicating some strength in the trend. However, the monthly RSI is bearish, suggesting potential weakness. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, and the daily moving averages are also mildly bullish. Dow Theory shows a mildly bullish stance on the monthly chart, but the weekly chart indicates no trend. The On-Balance Volume is mildly bearish on both weekly and monthly time frames. In terms of performance, Ikena has significantly outperformed the S&P 500 year-to-date with a return of 409.15% compared to the S&P's 12.22%, and over the past year, it has returned 403.01% versus the S&P's 17.14%. Overall, the current technical stance is mildly bullish, driven by the bullish...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
5.52%
EBIT to Interest (avg)
-56.34
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.93
Sales to Capital Employed (avg)
0.06
Tax Ratio
0.37%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.58
EV to EBIT
0.86
EV to EBITDA
0.87
EV to Capital Employed
-5.15
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-32.50%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 18 Schemes (18.47%)

Foreign Institutions

Held by 21 Foreign Institutions (3.51%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 67.44% vs 5.49% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.40",
          "val2": "-9.30",
          "chgp": "9.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.30",
          "val2": "-1.40",
          "chgp": "78.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.80",
          "val2": "-8.60",
          "chgp": "67.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -41.03% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 27.86% vs 0.87% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "9.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-54.10",
          "val2": "-74.40",
          "chgp": "27.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-49.20",
          "val2": "-68.20",
          "chgp": "27.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-8,233.30%",
          "chgp": "823.33%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-8.40
-9.30
9.68%
Interest
0.00
0.00
Exceptional Items
-0.30
-1.40
78.57%
Consolidate Net Profit
-2.80
-8.60
67.44%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 67.44% vs 5.49% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
9.20
-100.00%
Operating Profit (PBDIT) excl Other Income
-54.10
-74.40
27.28%
Interest
0.00
0.00
Exceptional Items
-4.40
0.00
Consolidate Net Profit
-49.20
-68.20
27.86%
Operating Profit Margin (Excl OI)
0.00%
-8,233.30%
823.33%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -41.03% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 27.86% vs 0.87% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Ikena Oncology, Inc. stock-summary
stock-summary
Ikena Oncology, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."